Addus HomeCare Corporation (ADUS) Q4 2025 Earnings Call Transcript

Addus HomeCare Corporation (ADUS) Q4 2025 Earnings Call Transcript

Seeking Alpha • 10 hours ago

Addus HomeCare to Participate in the Raymond James & Associates 47th Annual Institutional Investors Conference

FRISCO, Texas--(BUSINESS WIRE)--Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that management will participate in the Raymond James & Associates 47th Annual Institutional Investors Conference, which takes place March 1 – 4, 2026, in Orlando, Florida. In connection with the conference, there will be a live broadcast and replay of the Company's presentation available under the Investor Relations section of the Company's website, www.addus.com, st.

Business Wire • 14 hours ago

Addus HomeCare Announces Fourth Quarter and Year End 2025 Financial Results

FRISCO, Texas--(BUSINESS WIRE)--Addus HomeCare Corporation (NASDAQ: ADUS), a provider of home care services, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Highlights: Net Service Revenues Increase 25.6% to $373.1 Million Net Income of $29.8 Million, or $1.61 per Diluted Share Adjusted Net Income per Diluted Share Increases 28.3% year-over-year to $1.77 Adjusted EBITDA Increases 33.3% year-over-year to $50.3 Million Cash Flow f.

Business Wire • Feb 23, 2026

Addus HomeCare (ADUS) Beats Q4 Earnings and Revenue Estimates

Addus HomeCare (ADUS) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.38 per share a year ago.

Zacks Investment Research • Feb 24, 2026

Addus HomeCare (ADUS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Addus HomeCare (ADUS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Feb 24, 2026

Ahead of Addus HomeCare (ADUS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Addus HomeCare (ADUS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.

Zacks Investment Research • Feb 18, 2026

Addus HomeCare: A Perfect Setup For Organic Volume Growth

Addus HomeCare (ADUS) is positioned for accelerated organic growth, driven by recent reimbursement rate increases and a softening labor market in key states. ADUS's Personal Care segment, representing 72% of operating income, will benefit from improved hiring and wage competitiveness in Illinois and Texas. Hospice segment growth is robust, with 9.5% same-store patient growth and rising acuity, while the smaller Home Health segment faces headwinds from Medicare rate cuts.

Seeking Alpha • Feb 10, 2026

Addus HomeCare Announces Fourth Quarter and Year-End 2025 Earnings Release and Conference Call

FRISCO, Texas--(BUSINESS WIRE)--Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release earnings for the fourth quarter and year-ended December 31, 2025, on Monday, February 23, 2026, after the market close. Addus HomeCare will host a conference call on Tuesday, February 24, 2026, at 9:00 a.m. Eastern Time. Joining the call from the Company will be Dirk Allison, Chairman and CEO, Brian Poff, Executive Vice President and CFO, and Heather.

Business Wire • Feb 9, 2026

ADUS vs. USPH: Which Stock Is the Better Value Option?

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Addus HomeCare (ADUS) and U.S. Physical Therapy (USPH). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Dec 30, 2025

Addus HomeCare (ADUS) Upgraded to Buy: Here's What You Should Know

Addus HomeCare (ADUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Dec 24, 2025